OBJECTIVES: To evaluate the value of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT imaging in staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). METHODS: This retrospective analysis was conducted in 49 patients with GEP-NEN undergoing ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT imaging at our hospital from August, 2020 to March, 2023, including 34 newly diagnosed patients and 15 patients with recurrence or metastasis after treatment. GEP-NEN were classified into G1, G2, and G3 neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC) based on pathological typing. The detection efficiency were classified into 4 patterns based on the number of positive tumor lesions detected by the two tracers: ⁶⁸Ga-DOTATATE>¹⁸F-FDG (A); ⁶⁸Ga-DOTATATE=¹⁸F-FDG (B); ⁶⁸Ga-DOTATATE<¹⁸F-FDG (C); and complementation (D). The value of dual-modality imaging in staging and treatment decision were evaluated by visual analysis. RESULTS: In the 49 patients with GEP-NEN, ⁶⁸Ga-DOTATATE PET/CT was superior to ¹⁸F-FDG PET/CT for detecting systemic tumor lesions (P<0.001) and more sensitive for detecting primary/recurrent lesions, lymph node metastasis, liver metastasis, and bone metastasis (P<0.05), while ¹⁸F-FDG PET/CT had higher detection rates for lung metastasis and peritoneal metastasis (P<0.05). In terms of the detection efficiency, Pattern A was found in 46.9% (23/49) patients, Pattern B in 38.8% (19/49), Pattern C in 12.2% (6/49), and Pattern D in 2.0% (1/49). The complementary value of ¹⁸F-FDG PET/CT to ⁶⁸Ga-DOTATATE PET/CT was 0% in G1 NET patients (0/13), 8.3% in G2 NET patients (2/24), 50% in G3 NET patients (3/6), and 33.3% in NEC patients (2/6). 12.2% (6/49) of the patients had their staging confirmed or changed due to additional lesions detected by ¹⁸F-FDG PET/CT imaging, resulting subsequently in establishment or adjustment of their treatment plans. CONCLUSIONS ⁶⁸Ga-DOTATATE PET/CT imaging should be the primary choice for GEP-NEN patients. Additional ¹⁸F-FDG PET/CT imaging can potentially improve precision of staging and treatment decision-making for G2, G3 and NEC patients but provides virtually no clinical benefits for G1 NET patients.
Humans ; Positron Emission Tomography Computed Tomography/methods* ; Neuroendocrine Tumors/therapy* ; Pancreatic Neoplasms/therapy* ; Retrospective Studies ; Organometallic Compounds ; Stomach Neoplasms/therapy* ; Neoplasm Staging ; Fluorodeoxyglucose F18 ; Intestinal Neoplasms/therapy* ; Female ; Male ; Middle Aged ; Aged ; Adult

Flow diverter (FD) devices have gradually become the mainstream approach for interventional treatment of intracranial aneurysms. In-stent stenosis (ISS) is a common complication after FD implantation, which can lead to ischemic events and affect the prognosis of patients. Current studies have shown that ISS occurrence is closely related to hemodynamic changes. From the perspective of hemodynamics, this article reviews the research progress of mechanisms, evaluation methods and treatments of ISS after FD implantation, in order to provide reference for clinical practice.

[Objective] To explore the strategy of blood management in patients with massive transfusion in the frigid plateau region. [Methods] The treatment process of a patient with liver rupture in the frigid plateau region was analyzed, and the blood management strategy of the frigid plateau region was discussed in combination with the difficulties of blood transfusion and literature review. [Results] The preoperative complete blood count (CBC) test results of the patient were as follows: RBC 3.14×10¹²/L, Hb 10⁶ g/L, HCT 30.40%, PLT 115.00×10⁹/L; coagulation function: PT 18.9 s, FiB 1.31 g/L, DD > 6 μg/mL, FDP 25.86 μg/mL; ultrasound examination and imaging manifestations suggested liver contusion and laceration / intraparenchymal hematoma, splenic contusion and laceration, and massive blood accumulation in the abdominal cavity; it was estimated that the patient's blood loss was ≥ 2 000 mL, and massive blood transfusion was required during the operation; red blood cell components were timely transfused during the operation, and the blood component transfusion was guided according to the patient's CBC and coagulation function test results, providing strong support and guarantee for the successful treatment of the patient. The patient recovered well after the operation, and the CBC test results were as follows: RBC 4.32×10¹²/L, Hb 144 g/L, HCT 39.50%, PLT 329.00×10⁹/L; coagulation function: APTT 29.3 s, PT 12.1 s, FiB 2.728 g/L, DD>6 μg/mL, FDP 25.86 μg/mL. The patient was discharged after 20 days, and regular follow-up reexamination showed no abnormal results. [Conclusion] Individualized blood management strategy should comprehensively consider the patient’s clinical symptoms, the degree of hemoglobin decline, dynamic coagulation test results and existing treatment conditions. Efficient and reasonable patient blood management strategies can effectively improve the clinical outcomes of massive transfusion patients in the frigid plateau region.

Knee osteoarthritis (KOA) is a prevalent degenerative joint disease characterized by synovial inflammation, cartilage loss. Often manifesting as joint pain and limited mobility, it severely affects the quality of life of patients. Traditional treatment methods such as pharmacological injections and surgical interventions primarily aim to alleviate symptoms but have limited effects on cartilage repair. Human umbilical cord mesenchymal stem cells (hUC-MSCs), due to their anti-inflammatory and chondrogenic capabilities, is considered a new hope for the treatment of KOA. This article synthesizes the latest research findings from both domestic and international sources to discuss the theoretical basis for the clinical application of hUC-MSCs in treating KOA, clinical study design, and efficacy evaluation. It also addresses the challenges in the clinical application of hUC-MSCs and explores future directions, in the hope of providing feasible theoretical support for the treatment of KOA with hUC-MSCs.

In recent years, growing interest has been directed toward the application of platelet derivatives in regenerative medicine, cell therapy and targeted drug delivery. This article analyzes the basis and classification of platelet derivatives, discusses their clinical applications, and addresses main challenges such as the quantification and standardization of preparation process— particularly when used as individualized biologics, as well as the uncertainty and lack of comparability across experimental results. Countermeasures and improvements are provided, suggesting that standardized and normative management may offer new opportunities for the clinical use of platelet derivatives.

Circulating tumor cells (CTCs) have the ability to sow tumors and can be found in the peripheral blood of patients with precancerous lesions and healthy people. However, CTCs are not currently screened in the donors blood. A large number of allogeneic blood transfusions occurred worldwide each year, and allogeneic blood transfusions expose recipients to the risk of transmission and affect tumors associated with donor CTCs. Although leukocyte filtration can not completely remove tumor cells in the blood, it can effectively reduce the number of white blood cells in the blood and reduce their proliferation ability. Blood irradiation can effectively destroy the DNA of CTCs in the blood, and inhibit the occurrence and metastasis of tumors caused by the infusion of allogeneic blood containing CTCs. Therefore, we should pay attention to the potential risk of CTCs on clinical transfusion, and strengthen the preclinical treatment of blood to avoid donor-related tumor infection in blood recipients due to clinical transfusion.

Objective To evaluate the value of 68Ga-DOTATATE and 18F-FDG PET/CT imaging in staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms(GEP-NEN).Methods This retrospective analysis was conducted in 49 patients with GEP-NEN undergoing 18F-FDG and 68Ga-DOTATATE PET/CT imaging at our hospital from August,2020 to March,2023,including 34 newly diagnosed patients and 15 patients with recurrence or metastasis after treatment.GEP-NEN were classified into G1,G2,and G3 neuroendocrine tumors(NET)and neuroendocrine carcinomas(NEC)based on pathological typing.The detection efficiency were classified into 4 patterns based on the number of positive tumor lesions detected by the two tracers:68Ga-DOTATATE>18F-FDG(A);68Ga-DOTATATE=18F-FDG(B);68Ga-DOTATATE<18F-FDG(C);and complementation(D).The value of dual-modality imaging in staging and treatment decision were evaluated by visual analysis.Results In the 49 patients with GEP-NEN,68Ga-DOTATATE PET/CT was superior to 18F-FDG PET/CT for detecting systemic tumor lesions(P<0.001)and more sensitive for detecting primary/recurrent lesions,lymph node metastasis,liver metastasis,and bone metastasis(P<0.05),while 18F-FDG PET/CT had higher detection rates for lung metastasis and peritoneal metastasis(P<0.05).In terms of the detection efficiency,Pattern A was found in 46.9%(23/49)patients,Pattern B in 38.8%(19/49),Pattern C in 12.2%(6/49),and Pattern D in 2.0%(1/49).The complementary value of 18F-FDG PET/CT to 68Ga-DOTATATE PET/CT was 0%in G1 NET patients(0/13),8.3%in G2 NET patients(2/24),50%in G3 NET patients(3/6),and 33.3%in NEC patients(2/6).12.2%(6/49)of the patients had their staging confirmed or changed due to additional lesions detected by 18F-FDG PET/CT imaging,resulting subsequently in establishment or adjustment of their treatment plans.Conclusion 68Ga-DOTATATE PET/CT imaging should be the primary choice for GEP-NEN patients.Additional 18F-FDG PET/CT imaging can potentially improve precision of staging and treatment decision-making for G2,G3 and NEC patients but provides virtually no clinical benefits for G1 NET patients.

Kleine-Levin Syndrome(KLS)is a rare neurological disease characterized by recurrent episodes of hypersomnia, hyperphagia, hypersexuality, and cognitive and behavioral abnormalities, with complete functional recovery between episodes. Its pathogenesis remains unclear. We report a 33-year-old female with a 17-year clinical course, characterized mainly by recurrent hypersomnia. During episodes, the patient exhibited prominent anorexia, irritability, derealization, and disorientation, followed by brief periods of excitement after episode resolution. Inter-episode periods were entirely normal. Long-term polysomnography monitoring was conducted for a total of 7 792 minutes. Unlike the typical hyperphagia commonly observed in KLS, this case was marked by prominent anorexia, underscoring the clinical heterogeneity of KLS.This report adds to the limited documentation of rare cases in China.

Objective:To investigate the correlation between the expression levels of breast cancer metastasis-like transcriptional repressor (BRMS1L), keratin 19 (KRT19), microRNA-101 (miR-101) in surgical resection specimens and postoperative recurrence and metastasis of differentiated thyroid cancer (DTC) .Methods:A total of 186 DTC patients were selected in Shanxi Province Cancer Hospital from Jan. 2021 to Jan. 2023. Their recurrence and metastasis status were assessed in 2 years after surgery, and they were categorized into the recurrence and metastasis group and the non-recurrence and metastasis group. The clinical data of the two groups, as well as the expression levels of BRMS1L, KRT19, and miR-101 in the surgical resection specimens, were compared. Logistic regression analysis was used to investigate the relationship between BRMS1L, KRT19, miR-101 in the surgical resection specimens and postoperative recurrence and metastasis of DTC. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate the predictive value of BRMS1L, KRT19, and miR-101 in the surgical resection specimens for postoperative recurrence and metastasis of DTC, as well as their gain value in constructing predictive models.Results:Among 186 DTC patients were followed up for 2 years postoperatively, 4 were lost to follow-up. Of these, 137 did not experience recurrence or metastasis, while 45 did, resulting in a recurrence and metastasis rate of 24.73% (45/182). The tumor diameter, proportion of stage Ⅲ-Ⅳ, proportion of multiple lesions, and proportion of lymph node metastasis in the recurrent and metastatic group were all higher than those in the non-recurrent and non-metastatic group, while the proportion of postoperative 131I therapy was lower ( P<0.001, P=0.002, P=0.008, P<0.001). The KRT19 mRNA level in the recurrent and metastatic group was higher than that in the non-recurrent and non-metastatic group, while the BRMS1L mRNA and miR-101 levels were lower (both P<0.001). Logistic regression analysis showed that, before and after adjusting for other factors, BRMS1L, KRT19, and miR-101 were independent factors influencing postoperative recurrence and metastasis of DTC (both P<0.001). ROC curves showed that the AUCs of BRMS1L, KRT19, and miR-101 for predicting recurrent metastasis after DTC were 0.776, 0.802, 0.812, with sensitivities of 84.44%, 73.33%, and 84.44%, and specificities of 62.04%, 72.26%, and 79.56%; the R language package was used to construct a conventional prediction model consisting of clinical factors such as tumor diameter, clinical stage, lesion type, lymph node metastasis, and postoperative 131I treatment, and a new prediction model consisting of tumor diameter, clinical stage, lesion type, lymph node metastasis, postoperative 131I treatment, BRMS1L, KRT19, and miR-101. The test results indicated that both prediction models exhibited good fit ( P>0.05). The ROC curve analysis revealed that the AUCs for predicting postoperative recurrence and metastasis in DTC were 0.928 and 0.854 for the new and conventional prediction models, respectively. The sensitivity was 91.11% and 80.00%, and the specificity was 83.94% and 78.83%, respectively. The predictive value of the new prediction model was significantly better than that of the conventional prediction model ( Z=2.011, P=0.044) . Conclusions:The expression levels of BRMS1L, KRT19, and miR-101 in surgically resected specimens are closely correlated with postoperative recurrence and metastasis of DTC, serving as independent influencing factors with good predictive value. Furthermore, they exhibit significant gain value in constructing predictive models.

Objective:To investigate the correlation between the expression levels of breast cancer metastasis-like transcriptional repressor (BRMS1L), keratin 19 (KRT19), microRNA-101 (miR-101) in surgical resection specimens and postoperative recurrence and metastasis of differentiated thyroid cancer (DTC) .Methods:A total of 186 DTC patients were selected in Shanxi Province Cancer Hospital from Jan. 2021 to Jan. 2023. Their recurrence and metastasis status were assessed in 2 years after surgery, and they were categorized into the recurrence and metastasis group and the non-recurrence and metastasis group. The clinical data of the two groups, as well as the expression levels of BRMS1L, KRT19, and miR-101 in the surgical resection specimens, were compared. Logistic regression analysis was used to investigate the relationship between BRMS1L, KRT19, miR-101 in the surgical resection specimens and postoperative recurrence and metastasis of DTC. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate the predictive value of BRMS1L, KRT19, and miR-101 in the surgical resection specimens for postoperative recurrence and metastasis of DTC, as well as their gain value in constructing predictive models.Results:Among 186 DTC patients were followed up for 2 years postoperatively, 4 were lost to follow-up. Of these, 137 did not experience recurrence or metastasis, while 45 did, resulting in a recurrence and metastasis rate of 24.73% (45/182). The tumor diameter, proportion of stage Ⅲ-Ⅳ, proportion of multiple lesions, and proportion of lymph node metastasis in the recurrent and metastatic group were all higher than those in the non-recurrent and non-metastatic group, while the proportion of postoperative 131I therapy was lower ( P<0.001, P=0.002, P=0.008, P<0.001). The KRT19 mRNA level in the recurrent and metastatic group was higher than that in the non-recurrent and non-metastatic group, while the BRMS1L mRNA and miR-101 levels were lower (both P<0.001). Logistic regression analysis showed that, before and after adjusting for other factors, BRMS1L, KRT19, and miR-101 were independent factors influencing postoperative recurrence and metastasis of DTC (both P<0.001). ROC curves showed that the AUCs of BRMS1L, KRT19, and miR-101 for predicting recurrent metastasis after DTC were 0.776, 0.802, 0.812, with sensitivities of 84.44%, 73.33%, and 84.44%, and specificities of 62.04%, 72.26%, and 79.56%; the R language package was used to construct a conventional prediction model consisting of clinical factors such as tumor diameter, clinical stage, lesion type, lymph node metastasis, and postoperative 131I treatment, and a new prediction model consisting of tumor diameter, clinical stage, lesion type, lymph node metastasis, postoperative 131I treatment, BRMS1L, KRT19, and miR-101. The test results indicated that both prediction models exhibited good fit ( P>0.05). The ROC curve analysis revealed that the AUCs for predicting postoperative recurrence and metastasis in DTC were 0.928 and 0.854 for the new and conventional prediction models, respectively. The sensitivity was 91.11% and 80.00%, and the specificity was 83.94% and 78.83%, respectively. The predictive value of the new prediction model was significantly better than that of the conventional prediction model ( Z=2.011, P=0.044) . Conclusions:The expression levels of BRMS1L, KRT19, and miR-101 in surgically resected specimens are closely correlated with postoperative recurrence and metastasis of DTC, serving as independent influencing factors with good predictive value. Furthermore, they exhibit significant gain value in constructing predictive models.